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Abstract  58 
Development of SARS-CoV-2 vaccines and therapeutics will depend on understanding viral 59 
immunity. We studied T-cell memory 42 patients following recovery from COVID-19 (28 mild, 60 
14 severe, 16 unexposed donors), using IFNγ-based assays with peptides spanning SARS-61 
CoV-2 except ORF1. The breadth and magnitude of T-cell responses were significantly 62 
higher in severe compared to mild cases. Total and spike-specific T-cell responses 63 
correlated with spike-specific antibody responses.  We identified 41 peptides containing 64 
CD4+ and/or CD8+ epitopes, including six immunodominant regions.  Six optimised CD8+ 65 
epitopes were defined, with peptide-MHC-pentamer-positive cells displaying central- and 66 
effector-memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific 67 CD8+ T-cells were observed. The identification of T-cell responses associated with milder 68 
disease, will support an understanding of protective immunity, and highlights the potential of 69 
including non-spike proteins within future COVID-19 vaccine design. 70 
  71 
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Introduction  72 
 73 
COVID-19 is caused by the recently emerged Severe Acute Respiratory Syndrome 74 
coronavirus-2 (SARS-CoV-2). Whilst the majority of COVID-19 infections are relatively mild, 75 
with recovery typically within two to three weeks1, 2, a significant number of patients develop 76 
severe illness, which is postulated to be related to both an overactive immune response and 77 
viral-induced pathology3, 4. The role of T-cell immune responses in disease pathogenesis 78 
and longer-term protective immunity is currently poorly defined, but essential to understand 79 
in order to  inform  therapeutic interventions and vaccine design.  80 
 81 
Currently, there are many ongoing vaccine trials, but it is unknown whether they will provide 82 
long lasting protective immunity.  Most vaccines are designed to induce  antibodies to the 83 
SARS-CoV-2 spike protein, but it is not yet known if this will be sufficient to induce full 84 
protective immunity to SARS-CoV-25,6, 7,8. Studying natural immunity to the virus, including 85 
the role of SARS-CoV-2-specific T-cells is critical to fill the current knowledge gaps for 86 
improved vaccine design. 87 
 88 
For many primary virus infections, it typically takes 7-10 days to prime and expand adaptive 89 
T-cell immune responses in order to control the virus9. This coincides with the typical time it 90 
takes for COVID-19 patients to either recover or develop severe illness. There is an 91 
incubation time of 4-7 days before symptom onset, and a further 7-10 days before 92 
individuals progress to severe disease10. Such a pattern of progression raises the possibility 93 
that a poor T cell response contributes to SARS-CoV-2 viral persistence and COVID-19 94 
mortality, whereas strong T cell responses are protective in the majority of individuals. 95 
 96 
Evidence supporting a role for T cells in COVID-19 protection and pathogenesis is currently 97 
incomplete and sometimes conflicting3,11,12,13,14. To date there have been few studies 98 
analysing SARS-CoV-2-specific T-cell responses and their role in disease progression 15, 99 
 6
although virus specific T cells have been shown to be protective in human influenza 100 
infection16. In a study of CD4+ and CD8+ T-cell responses to SARS-CoV-2 in non-101 
hospitalised convalescent subjects, Grifoni et al  found that all recovered subjects 102 
established CD4+ responses and 70% established CD8+ memory responses to SARS-CoV-103 
217. SARS-CoV-2-specific CD4+ T-cell responses were also frequently observed in 104 
unexposed subjects in their study, suggesting the possibility of pre-existing cross-reactive 105 
immune memory to seasonal coronaviruses. In Singapore, Le Bert et al18  found long lasting 106 
T cell immunity  to the original SARS coronavirus nucleoprotein  (NP) in those that were 107 
infected in 2003. These T cells cross-reacted with SARS-CoV-2 NP, and T cells cross 108 
reactive  with NSP7 and NSP13 of other coronaviruses were also present in those 109 
uninfected with either SARS coronaviruses18. 110 
 111 
In the present study, the overall and immunodominant SARS-CoV-2–specific memory T-cell 112 
response in subjects who had recovered from COVID-19 were evaluated ex vivo using 113 
peptides spanning the full proteome of the SARS-CoV-2, except for ORF-1. Epitopes were 114 
identified using two-dimensional matrix peptide pools and CD4+ and CD8+ T cell responses 115 
were distinguished. The epitope specificity and HLA restriction of the dominant CD8+ T-cell 116 
responses were defined in ex vivo  assays and using in vitro cultured short-term T-cell lines.  117 
The ex vivo functions of SARS-CoV-2-specific T-cells specific for dominant epitopes were 118 
evaluated by their intracellular cytokine production profiles. Broad, and frequently strong, 119 
SARS-CoV-2 specific CD4+ and CD8+ T-cell responses were seen in the majority of 120 
convalescent patients, with significantly larger overall T-cell responses in those that had 121 
severe compared to mild disease.  However, there was a greater proportion of CD8+ T-cell 122 
compared to CD4+ T cell responses in mild cases with higher frequencies of multi-cytokine 123 




Study subjects 127 
42 individuals were recruited following recovery from COVID-19, including 28 mild cases and 128 
14 severe cases. In addition, 16 control individuals sampled in 2017-2019, before COVID-19 129 
appeared, were studied in parallel.  Supplementary Fig. 1 shows the participant 130 
characteristics.  No significant differences in gender or age were noted between mild and 131 
severe groups. The SaO2/FiO2 ratio in severe cases ranged from 4.3 (where 4.5 would be 132 
the estimate for an individual with mild disease breathing ambient air) to 1.6 with the patients 133 
with critical disease having an estimate of 0.8 (median in severe group 3.8). 134 
 135 
Ex vivo assessment of memory T cell responses specific to SARS-CoV-2  136 
PBMCs were tested for responses to a panel of 423 overlapping peptides spanning the 137 
SARS-CoV-2 proteome except ORF1, using ex vivo IFN-γ ELISpot assays. All overlapping 138 
peptides were placed into two 2-dimensional peptide matrices: a total of 61 peptide pools 139 
were tested, with 29 peptides in the first-dimension pools, as described in Supplementary 140 
Table 1. The majority of the participants exhibited SARS-CoV-2 memory T cell responses to 141 
at least one of the peptides. The overall distribution,  magnitude  and breadth of the IFN-γ 142 
responses against all SARS-CoV-2 virus peptides are shown in Fig. 1. There was no 143 
correlation between the T cell responses and the time that had elapsed from symptom 144 
development (Supplementary Fig. 2).  No ex vivo IFNγ-producing SARS-CoV-2-specific T 145 
cell responses were observed in healthy volunteers, who were all sampled before any 146 
chance of exposure, but in those with appropriate HLA types, T cell responses were 147 
observed to influenza virus, EBV, CMV (FEC) using pools of known T cell epitopes as well 148 
as PHA as positive controls  (Supplementary Fig. 3). The breadth and magnitude of the T 149 
cell responses varied considerably between individuals. T cell responses were detected 150 
against epitopes distributed across a wide variety of virus proteins. Significantly higher 151 
magnitude (p=0.002) and broader (p=0.002) overall T cell responses were observed in 152 
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severe cases in comparison with mild cases, in particular for responses to spike 153 
(magnitude/breadth, p=0.021/0.016), membrane (magnitude/breadth, p<0.001/p=0.033), 154 
ORF3 (magnitude/breadth, p<0.001/0.001) and ORF8 (magnitude/breadth, p=0.011/0.014)  155 
proteins (Fig. 2).  156 
 157 
Correlation with spike specific antibody responses 158 
The relationship between spike-specific, and overall T cell responses in association with 159 
spike-specific, receptor binding domain (RBD) and NP-specific antibody endpoint titres 160 
(EPTs) was assessed (Fig. 3). There were significant correlations between (a) spike-specific 161 
antibody titers and both overall T cell responses (p<0.001/R=0.52) and spike-specific T cell 162 
responses (p=0.001/R=0.51); (b) RBD-specific antibody titers and both overall T cell 163 
responses (p<0.001/R=0.52) and spike-specific T cell responses (p<0.001/R=0.52);  and (c) 164 
NP-specific antibody titers and both overall T cell responses (p=0.002/R=0.47) and spike-165 
specific T cell responses (p=0.007/R=0.41). However, there was no significant association 166 
between NP-specific antibody titers and NP-specific T cell responses (p=0.067/R= 0.29); 167 
(Fig. 3a-c; and Supplementary Fig. 4). Moreover, significantly higher level of spike, RBD and 168 
NP EPTs were observed in severe cases in comparison with mild cases (Fig. 3d). It was 169 
noted that some individuals had low RBD-specific antibodies (Fig. 3b), yet had detectable 170 
spike-specific antibodies (Fig. 3a), suggesting that antibodies were able to target non-RBD 171 
regions of spike – these are under further investigation. 172 
 173 
Distribution of SARS-CoV-2–specific CD4+ and CD8+ memory T cell responses  174 
Having identified overall T cell responses to SARS-CoV-2 peptides, the responses detected 175 
against positive peptide pools were characterized by flow cytometry for peptide recognition 176 
by CD4+ or CD8+ T cell subsets and for intracellular production of IFN-γ, TNF-α and IL-2 177 
after stimulation (Fig. 4a-b and Supplementary Fig. 5).  A greater proportion of the T cell 178 
responses to spike (p=0.0268) and M/NP (p=0.02) were contributed to by CD8+ T cells in 179 
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those with mild disease compared to those with severe disease (Fig. 4c, supplementary Fig. 180 
6a)  181 
 182 
Evaluation of the polyfunctionality of T cells responding to SARS-CoV-2 peptides 183 
Multi-cytokine analysis revealed patterns of IFNγ, TNFα and IL-2 production by CD4+ and 184 
CD8+ T cells in both mild and severe cases (Fig. 5a), For 22 individuals tested, both CD4+ 185 
and CD8+ antigen-specific-T cells produced least one of these three cytokines and others in 186 
combination. CD8+ but not CD4+ T cells targeting different virus proteins showed different 187 
cytokine profiles, with the M/NP-specific CD8+ T cells showing wider functionality than T cells 188 
targeting spike protein (p=0.0231, Fig. 5b and supplementary Fig. 6b). Furthermore, there 189 
were a greater proportion of multifunctional M/NP-specific CD8+ T cells compared to spike-190 
specific T cells in those that had mild disease (p=0.0037), but not in those that had severe 191 
disease (p=0.3823). In contrast to observations seen in influenza virus infection19 , we did 192 
not observe significant differences in the cytotoxic potential (as indicated by expression of 193 
the degranulation marker CD107a) in patients with mild and severe disease (Fig. 5c); and 194 
we observed very few CD107a+ CD4+ T cells overall, suggesting cytotoxic CD4+ T cells 195 
might not be a major contributor to virus clearance.  196 
 197 
Identification of SARS-CoV-2 specific T cell peptides containing epitopes  198 
IFNγ ELISpot assays were performed with candidate peptides identified from the 2-199 
dimensional matrix analysis in 34 subjects. A total of 41 peptides containing SARS-CoV-2 T 200 
cell epitope regions were recognized by COVID-19 convalescent subjects, 18 from spike, 10 201 
from NP, 6 from membrane and 7 from ORF proteins.  Strikingly, 6 dominant 18mer peptides 202 
were recognised by 6 or more of 34 subjects tested (Table 1). NP-16 was recognised by 203 
12/34 (35%) subjects tested and contained at least two epitopes which recognised by either 204 
CD4+ T cells or CD8+ T cells. 205 
 206 
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M-24 was recognised by 16/34 subjects (47%) tested and contained one or more CD4+ T 207 
cell epitopes. Peptide M-20 was recognised by 11/34 subjects tested (32%) and contained 208 
one or more CD4+ T cell epitopes. 3 dominant spike peptides were also identified, with S-34 209 
recognised by 10/34 subjects (29%) containing both CD4+ and CD8+ T cell epitopes, and a 210 
further two spike peptides S-151 and S-174 were recognised by 8/34 and 6/34 subjects (24% 211 
and 18%), both containing CD4+ T cell epitopes.  212 
 213 
Those dominant responses were further confirmed by ex-vivo assays and by using cultured 214 
short-term T cell lines. Supplementary Fig. 7 illustrates examples of FACS plots from 215 
intracellular cytokine staining (ICS) when short-term T cell lines were stimulated with single 216 
peptides containing epitopes. CD4+ T cells elicited strong responses against dominant spike 217 
peptides and M peptides, whereas cells targeting two NP dominant peptides were CD8+ T 218 
cells. The optimal epitopes within the long peptides recognized by dominant CD8+ T cells 219 
and their HLA restriction, matched to the donor’s HLA type,  were predicted using the  IEDB 220 
analysis resource  (http://tools.iedb.org/mhci). The best predicted epitope sequences are 221 
shown in supplementary Table 2.   222 
 223 
A set of previously defined SARS epitopes20 with identical sequences to SARS-CoV-2 were 224 
also tested by ELISpot assay  (Supplementary table 3),  Most of those peptides did not elicit 225 
any positive responses in 42 COVID-19 recovered subjects, apart from two NP epitope 226 
peptides (N-E-3 MEVTPSGTWL and N-E-11 LLNKHIDAYKTFPPTEPK) and one spike 227 
epitope peptide (S-E-19 QLIRAAEIRASANLAATK) . N-E-11, which is identical to peptide 228 
NP-51, shares the sequence with two other known HLA-A*0201 restricted SARS epitopes 229 
(N-E-1 ILLNKHID and N-E-5 ILLNKHIDA). Interestingly, one of the responders to this 230 
peptide did not carry the HLA-A*0201 allele (Table 1), indicating this peptide may contain a 231 
different SARS-CoV-2 epitope presented by a different HLA molecule. Whereas these NP 232 
epitopes are targeted by CD8+ T cells, we also detected a CD4+ T cell response targeting 233 
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SARS spike epitope S-E-19 which spans between the overlapping peptides of S-203 and S-234 
204. This peptide is known to be presented by HLA-DRB1*0401 in SARS infection. 235 
 236 
The  optimal peptide sequences and their HLA restrictions were confirmed by generating 237 
short term T cell lines and clones, which were tested in ELIspot assays by co-culturing with 238 
peptide loaded HLA matched and unmatched immortalized B lymphoblastoid cell lines 239 
(BCLs) as previously described21. In total 6 CD8+ T cell epitopes restricted by HLA-A*0101, 240 
A*0301, A*1101, B*0702, B*4001 and B*2705 were confirmed (Fig. 6a).  HLA-peptide 241 
pentamers were synthesized comprising 5 peptides bound to the appropriate HLA class I 242 
molecules.  T cell staining was verified by flowcytometry (Fig. 6b) and their phenotypes were 243 
determined (Fig. 7). A pentameric HLA-A*0201 with the spike epitope reported 244 
by Shomuradova  et al22, was synthesised. Only one  out of six HLA-A*0201-positive donors 245 
showed detectable staining, but at a very low frequency.  The majority of pentamer stained 246 
SARS-Cov-2 specific CD8+ T cells exhibited central memory (20.7%±8.4%) or effector 247 
memory phenotypes (50.3%±13.3%) (Fig. 7) and early (CD27+CD28+, 43.8%±20.9%) or 248 
intermediate (CD27+CD28-, 49.3%±21.0%) differentiation phenotypes. 249 
 250 
Discussion 251 
This study demonstrates the presence of robust memory T cell responses specific for SARS-252 
CoV-2 in the blood of donors who have recovered from Covid-19. The broader and stronger 253 
SARS-CoV-2 specific T cell responses in patients who had severe disease may be the result 254 
of higher viral loads and may reflect a poorly functioning early T cell response that failed to  255 
control the virus, in addition to other factors such as direct virus-induced pathology 256 
associated with larger viral inoculums or poorer innate immunity. Alternatively, it is possible 257 
that the T cell response was itself harmful and contributes to disease severity. Consistent 258 
with recent reports from Grifoni et al and Sekine et al 17, 23,  a particularly high frequency of 259 
spike protein-specific CD4+ T cell responses was observed in patients who had recovered 260 
from COVID-19. This is very similar to influenza virus infection, where viral surface 261 
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hemagglutinin (HA) elicited mostly CD4+ T cell responses, whereas the majority of CD8+ T 262 
cell responses were specific to viral internal proteins 24. Understanding the roles of different 263 
subsets of T cells in protection or  pathogenesis is a crucial question for COVID-19. The 264 
timing and strength of the first  T cell responses, could be critical in determining this balance 265 
at an early stage of the infection.  266 
  267 
Among the 41 peptides containing T cell epitopes that were identified in this study, six 268 
immunodominant epitope groups (peptides) were  frequently targeted by T cells in many 269 
donors, including three in spike (29%, 24%, 18%), two in membrane protein (32%, 47%) and 270 
one in nucleoprotein (35%).  The immunodominant peptide regions identified here may 271 
include multiple epitopes restricted by different HLAs (both class I and II, such as S-34 and 272 
NP16)  with immunodominance preferences imposed by the antigen processing pathways. 273 
Whether or not these dominant responses play a role in immune protection merits further 274 
investigation in larger prospective cohorts.  275 
 276 A higher proportion of CD8+ T cell responses was observed in mild disease, suggesting 277 the potential protective role of CD8+ T cell responses in mild disease or pathogenic role 278 of CD4+ T cell responses in severe disease which merits further investigation.  279 
 280 
The majority of pentamer-binding CD8+ T cells were effector memory and central memory 281 
with early and intermediate differentiation phenotypes, with functional potential on antigen 282 
re-exposure. Because the number of donors studied was limited and they would likely show 283 
diverse TCRs, peptide/MHC affinities and antigen sensitivities for the different epitopes, it 284 
was not possible to make a detailed analysis comparing mild and severe cases. However, 285 
the groundwork, including epitope identification, was laid for future studies that can address 286 
this important issue. 287 
 288 
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Multiple strong dominant T cell responses were seen in study subjects, specific for the M 289 
and NP proteins. Dominant epitope regions within NP (NP-16) were detected in 35% of 290 
study subjects and M (M-20 and M24) were detected in 32% and 47%. In addition, a higher 291 
proportion of multi-cytokine producing M/NP-specific compared to spike-specific CD8+ T 292 
cells was observed in subjects who had recovered from mild disease. A similar trend was 293 
also observed in severe cases, although was not significant possibly due to fewer cases.  294 
These data strongly suggest NP and M have potential for inclusion within future vaccines so 295 
as to stimulate strong effector T cell responses. Furthermore, T cells responding to these 296 
antigens may be more cross-reactive 18. 297 
 298 
 IFN-γ producing SARS-CoV-2 specific T cell responses were not observed in 16 healthy 299 
unexposed volunteers differing from recently published reoorts by Grifoni et al17  and  Braun 300 
et al25, both of which used peptide stimulated induction of activation markers (AIM) assays.   301 
On the other hand, in a recent immunogenicity study of a recombinant adenovirus type-5 302 
(Ad5) vectored COVID-19 vaccine human phase I trial in 108 volunteers without pre-303 
exposure to COVID-19), spike-specific T cell responses, measured IFN-γ ELISpot and 304 
intracellular cytokine stimulation (ICS) assays, were not found before vaccination6. These 305 
differences could result from differences in sensitivity of the detection methods, AIM versus. 306 
IFN-γ production assays.  IFN-γ -ELISpot and ICS are well-established methods for 307 
evaluating antigen specific T cells, used in different virus infections and vaccine studies, that 308 
have direct functional relevance 24, 26, 27, 28. The AIM assay is more recently developed assay, 309 
capable of detecting early responding T cells, that is independent of cytokine production. 310 
Both methods are valid but differ in sensitivity and possible functional relevance.  However, it 311 
is also possible that different circulating coronaviruses have been previously present in the 312 
different geographical populations studied, giving cross reactive responses in some regions 313 
but not others, as suggested by Le Bert et al18 .  These T-cell cross reacting viruses could 314 
include not only SARS-CoV-1 and  human “common cold” coronaviruses, but also other 315 
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unknown coronaviruses of animal origin.  It is also known that very sensitive assays can 316 
detect not only  pre-existing naïve antigen specific CD4+ T cells but also memory CD4+ T 317 
cells. The latter are potentially primed by other microbes that cross react with viruses as 318 
diverse as CMV, HIV-1 and Ebolavirus in most unexposed humans 29, 30.  Therefore, similar 319 
findings with SARS-CoV-2 peptides do not necessarily mean the T cells were primed by 320 
previous infecting coronaviruses. Indeed, the implications of  pre-existing cross-reactivity to 321 
seasonal coronavirus and other viruses for COVID-19 immunity merits further detailed 322 
investigation as nicely highlighted by Sette A and Crotty S31 . 323 
 324 
This study focuses on T cell responses in PBMC. There remains a lack of understanding of 325 
memory T cells (Trm) at the site of infection, which is likely providing the most potent 326 
protection as observed in influenza virus infection32. It is possible that the hierarchy of 327 
immunodominant circulating blood memory T cell pools may not exactly  reflect that of Trm 328 
in the lung17, 33, 34. Therefore, understanding the features of tissue resident memory T cells 329 
and their association with disease severity will be critical and also merits further investigation. 330 
 331 
Taken together, this study has demonstrated strong and broad SARS-CoV-2-specific CD4+ 332 
and CD8+ T cell responses in the majority of humans who had recovered from COVID-19. 333 
The immunodominant epitope regions and peptides containing T cell epitopes identified in 334 
this study will provide critical tools to study the contribution of SARS-CoV-19 specific T cells 335 
in protection and immune pathology. Identification of non-spike dominant CD8+ T cell 336 
epitopes, suggests the potential importance of including of non-spike protein such as NP, M 337 
and ORFs into future vaccine designs.  338 
 339 
  340 
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Materials and methods 341 
 342 
Ethical Statement 343 
Patients were recruited   from the John Radcliffe Hospital in Oxford, UK, between March and 344 
May 2020 by identification of patients hospitalised during the SARS-COV-2 pandemic and 345 
recruited into the Sepsis Immunomics and ISARIC Clinical Characterisation Protocols (IRAS 346 
260007 and IRAS126600). Patients were sampled at least 28 days from the start of their 347 
symptoms. Unexposed healthy adult donor samples were used from unrelated studies 348 
undertaken between 2017-early 2019. Written informed consent was obtained from all 349 
patients.  350 
  351 
Clinical definitions 352 
All patients were confirmed to have a test positive for SARS-CoV-2 using reverse 353 
transcriptase polymerase chain reaction (RT-PCR) from an upper respiratory tract 354 
(nose/throat) swab tested in accredited laboratories. The degree of severity was identified as 355 
mild, severe or critical infection according to recommendations from the World Health 356 
Organisation. Patients were classified as ‘mild’ if they did not require oxygen (that is, their 357 
oxygen saturations were greater than 93% on ambient air) or if their symptoms were 358 
managed at home. A large proportion of our mild cases were admitted to hospital for public 359 
health reasons during the early phase of the pandemic even though they had no medical 360 
reason to be admitted to hospital. Severe infection was defined as COVID-19 confirmed 361 
patients with one of the following conditions: respiratory distress with RR>30/min; blood 362 
oxygen saturation<93%; arterial oxygen partial pressure (PaO2) / fraction of inspired O2 363 
(FiO2) <300mmHg; and critical infection was defined as respiratory 364 
failure requiring mechanical ventilation or shock; or other organ failures requiring admission 365 
to ICU. Since the Severe classification could potentially include individuals spanning a wide 366 
spectrum of disease severity ranging from patients receiving oxygen through a nasal 367 
cannula through to non-invasive ventilation we also calculated the SaO2/FiO2 ratio at the 368 
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height of patient illness as a quantitative marker of lung damage. This was calculated by 369 
dividing the oxygen saturation (as determined using a bedside pulse oximeter) by the 370 
fraction of inspired oxygen (21% for ambient air, 24% for nasal cannulae, 28% for simple 371 
face masks and 28, 35, 40 or 60% for Venturi face masks or precise measurements for non-372 
invasive or invasive ventilation settings). Patients not requiring oxygen with oxygen 373 
saturations (if measured) greater than 93% on ambient air, or managed at home were 374 
classified as mild disease. Viral swab Ct values were not available for all patients. In addition, 375 
we have standardised all of our analyses to the days since symptom onset. 376 
 377 
Synthetic peptides 378 
A total of 423 15- to 18-mer peptides overlapping by 10 amino acid residues and spanning 379 
the full proteome of the SARS-CoV-2 except ORF-1 (Supplementary Table 1) were designed 380 
using software PeptGen (http://www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html) 381 
and synthesized (purity >75%; Proimmune).  382 
27 previously defined SARS epitopes20 were also synthesised (Supplementory Table 383 
2).Pools of Cytomegalovirus (CMV),Epstein-Barr cirus (EBV) and influenza virus specific 384 
epitope peptides and The human immunodeficiency viruses (HIV) gag were also used as 385 
positive and negative controls.  386 
 387 
2-dimensional peptide matrix system 388 
The overlapping peptides spanning the SARS-CoV-2 were assigned into a 2-dimensional 389 
matrix system in which each peptide was represented in 2 different peptide pools. Each 390 
peptide pool contains no more than 16 individual peptides. The first dimension of the peptide 391 
matrix system was designed so that peptides from different source proteins were separated 392 
into different pools. (Supplemental Table 1).  393 
 394 
Ex vivo ELISpot assay  395 
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IFN-γ ELISpot assays were performed using either freshly isolated or cryopreserved PBMCs 396 
as described previously. No significant difference was observed between responses 397 
generated by fresh or cryopreserved PBMCs as described previously24, 35. 398 
 399 
Overlapping peptides were pooled  and then added to 200,000 PBMCs per test at the final 400 
concentration of 2μg/mL for 16–18 h, the positive responses were confirmed by repeat 401 
ELISPOT assays. To quantify antigen-specific responses, mean spots of the control wells 402 
were subtracted from the positive wells, and the results expressed as spot forming units 403 
(SFU)/106 PBMCs. Responses were considered positive if results were at least three times 404 
the mean of the negative control wells and >25SFU/106PBMCs. If negative control wells 405 
had >30SFU/106 PBMCs or positive control wells (PHA stimulation) were negative, the 406 
results were excluded from further analysis. 407 
 408 
Determination of plasma binding to trimeric spike, RBD and NP by ELISA 409 
MAXISORP immunoplates (442404; NUNC) were coated with 0.125μg of StrepMAB-Classic 410 
(2-1507-001;iba) , blocked with 2% skimmed milk in PBS for one hour and then incubated 411 
with 50μL of 5μg/mL soluble trimeric Spike 2μg/mL or 2% skim milk in PBS. After one hour, 412 
50 μL of serial two-fold dilutions of plasma, from 1:50 to 1:51200 in PBS containing 2% 413 
skimmed milk were added followed by ALP-conjugated anti-human IgG (A9544; Sigma) at 414 
1:10,000 dilution. The reaction was developed by the addition of PNPP substrate and 415 
stopped with NaOH. The absorbance was measured at 405nm. Endpoint titers (EPTs) were 416 
defined as reciprocal plasma dilutions that corresponded to two times the average OD 417 
values obtained with mock. To determine EPTs to RBD and NP, immunoplates were coated 418 
with 0.125ug of Tetra-His antibody (34670; QIAGEN) followed by 2μg/mL and 5μg/mL of 419 
soluble RBD and NP, respectively. 420 
 421 
Intracellular cytokine staining (ICS)  422 
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Intracellular cytokine staining was performed as described previously36, 37 .  Briefly, overnight 423 
rested PBMCs were stimulated with pooled or individual peptides at a final concentration of 424 
10μg/mL for 1 h in the presence of 2μg/mL monoclonal antibodies CD28 and CD49d, and  425 
then for an additional 5h with GolgiPlug, GolgiStop and surface stained with PE-anti-CD107a. 426 
Dead cells were labelled using LIVE/DEAD™ Fixable Aqua dye from Invitrogen; surface 427 
markers including BUV395-anti-CD3, BUV737-anti-CD4, PerCP-Cy5.5-anti-CD8, BV510-428 
anti-CD14 (Biolegend), BV510-anti-CD16 (Biolegend) and BV510-anti-CD19 (Biolegend) 429 
were stained. Cells were then washed, fixed with Cytofix/CytopermTM and stained with PE-430 
Cy7-anti-IFNγ, APC-anti-TNFα (eBioscience), BV421-anti-IL-2 (Biolegend). Negative 431 
controls without peptide-stimulation were run for each sample. All reagents were from BD 432 
Bioscience unless otherwise stated. All samples were acquired on BD LSR Fortessa (BD 433 
Biosciences) flow cytometer and analyzed using FlowJoTM v.10 software (FlowJo LLC). To 434 
determine the frequency of different response patterns based on all possible combinations, 435 
Boolean gates were created using IFN-γ, TNF-α and IL-2. Cytokine responses were 436 
background subtracted individually prior to further analysis.  437 
 438 
Pentamer phenotyping 439 
Cryopreserved PBMCs were thawed as described above. A total of 1 × 106 live PBMCs were 440 
labeled with peptide-MHC class I Pentamer-PE (Proimmune, UK) and incubated for 15 min 441 
at 37°C. Dead cells were first labelled with LIVE/DEAD™ Fixable Aqua dye (Invitrogen) and 442 
then with surface markers CD3-BUV395, CD8-PerCP.Cy5.5, CD14-BV510 (Biolegend UK), 443 
CD16-BV510 (Biolegend UK), CD19-BV510 (Biolegend UK), CD28-BV711, CD27-APC-444 
R700, CD45RA-APC-H7 and CCR7-PE-Dazzel 594 (Biolegend UK). All reagents were from 445 
BD Bioscience unless otherwise stated. All samples were acquired on BD LSR Fortessa (BD 446 
Biosciences) flow cytometer and analyzed using FlowJoTM v.10 software (FlowJo LLC). 447 
 448 
Generating short-term T cell lines 449 
 19
Short-term SARS-CoV-2-specific T cell lines were established as previously described 35. 450 
Briefly, 3 × 106 to 5 × 106 PBMCs were pulsed as a pellet for 1 h at 37°C with 10 μM of 451 
peptides containing T cell epitope regions and cultured in R10 at 2 × 106 cells per well in a 452 
24-well Costar plate. IL-2 was added to a final concentration of 100U/mL on day 3 and 453 
cultured for further 10 -14 days.  454 
 455 
Statistical analysis 456 
Statistical analysis was performed with IBM SPSS Statistics 25 and Fig.s were made with 457 
GraphPad Prism 8. Chi-square tests were used to compare ratio difference between two 458 
groups. After testing for normality using Kolmogorov-Smirnov test, Independent-samples t 459 
test or Mann-Whitney U test was employed to compare variables between two groups. 460 
Correlations were performed via Spearman’s rank correlation coefficient. Statistical 461 
significance was set at *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.  All the tests were 462 
2-tailed.  463 
 464 
Data availability 465 
The data that support the findings of this study are available from the corresponding author 466 
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Table 1 Peptides containing T cell epitopes  639 
Peptide Position Amino Acid Sequence
CD4/CD8 
Response
No of subjects 
responded
Spike S-34 166-180 CTFEYVSQPFLMDLE 4/8 10
(n=18) S-39 191-205 EFVFKNIDGYFKIYS na 1
S-42 206-230 KHTPINLVRDLPQGF na 1
S-43 211-225 NLVRDLPQGFSALEP na 1
S-71 351-365 YAWNRKRISNCVADY 4 1
S-77 381-395 GVSPTKLNDLCFTNV 4 1
S-90 446-460 GGNYNYLYRLFRKSN na 1
S-91 451-465 YLYRLFRKSNLKPFE na 1
S-103 506-520 VVLSFELLHAPATVC 4 1
S-106 526-540 GPKKSTNLVKNKCVN 8 1
S-145 721-735 SVTTEILPVSMTKTS na 1
S-150 746-760 STECSNLLLQYGSFC na 1
S-151 751-765 NLLLQYGSFCTQLNR 4 8
S-161 801-815 NFSQILPDPSKPSKR 4 2
S-174 866-880 TDEMIAQYTSALLAG 4 6
S-235 1171-1185 GINASVVNIQKEIDR na 1
S-240 1196-1210 LIDLQELGKYEQYI na 1
S-242 1206-1220 YEQYIKWPWYIWLGF na 1
NP-1 1-17 MSDNGPQNQRNAPRITF 8 3
NP-2 8-25 NQRNAPRITFGGPSDSTG 8 3
NP NP-12 82-95 DQIGYYRRATRRIR na 1
(n=10) NP-15 101-113 MKDLSPRWYFYYL na 1
NP-16 104-121 LSPRWYFYYLGTGPEAGL 4/8 12
NP-46 313-330 AFFGMSRIGMEVTPSGTW na 1
NP-47 321-338 GMEVTPSGTWLTYTGAIK na 1
NP-48 329-346 TWLTYTGAIKLDDKDPNF 4 2
NP-50 344-361 PNFKDQVILLNKHIDAYK 4 1
NP-51 352-369 LLNKHIDAYKTFPPTEPK 8 3
M19 133-150 LLESELVIGAVILRGHLR na 3
M M-20 141-158 GAVILRGHLRIAGHHLGR 4 11
(n=6) M-21 149-166 LRIAGHHLGRCDIKDLPK na 3
M-23 165-181 PKEITVATSRTLSYYKL na 3
M-24 172-188 TSRTLSYYKLGASQRVA 4 16
M-28 201-218 IGNYKLNTDHSSSSDNIA na 1
ORFs ORF-3a-20 145-160 YFLCWHTNCYDYCIPY na 1
(n=7) ORF-3a-27 198-215 KDCVVLHSYFTSDYYQLY na 3
ORF-3a-28 206-225 YFTSDYYQLYSTQLSTDTGV 8 4
ORF-3a-30 224-243 GVEHVTFFIYNKIVDEPEEH na 1
ORF-7a-2 9-25 LITLATCELYHYQECVR na 3
ORF-7a-7 46-63 FHPLADNKFALTCFSTQF na 1
ORF-7a-10 69-86 DGVKHVYQLRARSVSPKL 4 1  640 
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Red highlights the overlaps of two adjacent peptides recognised by same subjects; Bold 641 
indicates multiple donor responders; Peptides with underline are the 6 immunodominant 642 
peptides. na: not available643 
 27
Figure Legends 644 
Fig. 1: Memory T cell responses specific to SARS-CoV-2 virus proteins in 42 645 
convalescent SARS-CoV-2-infected patients. 28 individuals had mild symptoms while 14 646 
showed severe symptoms. PBMC were isolated and IFNγ production was detected by 647 
ELISpot after incubation with SARS-CoV-2 peptides. a) Magnitude of IFNγ T cell responses 648 
from each individual. Each bar shows the total T cell responses of each individual specific to 649 
all the SARS-CoV-2 protein peptides tested. Each colored segment represents the source 650 
protein corresponding to peptide pools eliciting IFNγ T cell responses. b) Breadth of T cell 651 
responses from each individual. The breadth of T cell responses was calculated by the 652 
number of peptide pools in the first-dimension (total 29) cells responded to SFU spot forming 653 
units 654 
 655 
Fig. 2: Comparison of magnitude and breadth of T cell response specific to each viral 656 
protein between convalescent patients with mild symptoms and severe symptoms. 657 
PBMCs were isolated and IFNγ production was detected by ELISpot after incubation with 658 
SARS-CoV-2 peptides. a) and b) illustrate the magnitude and the breadth of T cell response 659 
against each viral protein between the groups with mild symptoms (n=28) and with severe 660 
symptoms (n=14), respectively. Data are presented as median with interquartile range. 661 
Mann-Whitney test was used for the analysis and two-tailed p value was calculated. *P<0.05, 662 
**P<0.01, ***P<0.001. SFU spot forming units; 663 
 664 
Fig. 3: Correlation of T cell responses against SARS-CoV-2 with Spike, RBD and NP-665 
specific antibody responses. a) EPTs-spike b) EPTs-RBD and c) EPTs-NP in association 666 
with overall T cell responses. Red dots represent the patients with severe symptoms 667 
whereas the mild cases are shown as black dots. n=42. Spearman’s rank correlation 668 
coefficient was used for the correlation analysis. d) Comparison of EPT-spike (p<0.0001), 669 
EPT-RBD (p<0.0001) and EPT-NP (p=0.0004) with mild symptoms (n=28) and severe 670 
 28
symptoms (n=14). Data are presented as median with interquartile range and Mann-Whitney 671 
test was used for comparison. Two-tailed p value was calculated. *** P<0.001; **** P<0.0001 672 
EPT: Endpoint titer 673 
 674 
Fig. 4: Distribution of SARS-CoV-2–specific CD4+ and CD8+ memory T cell responses  675 
Cytokine producing T cells were detected by ICS after incubation with SARS-CoV-2 peptides. 676 
a) and b) FACS plots represent CD4+T cell and CD8+ T cells expressing IFNγ (x-axis),TNFα 677 
(y-axis) and/or IL-2 (y-axis) upon stimulation with respective SARS-CoV-2 peptide pools in 678 
examples of mild and severe cases. c) Comparison of relative proportion of SARS-CoV-2 679 
peptide pool-reactive CD8+ T cells between mild and severe cases. The SARS-CoV-2 680 
peptide pool-reactive CD4+ or CD8+ T cells were identified with at least one of the three 681 
cytokines detected: IFNγ, TNFα and IL-2. The frequencies of SARS-CoV-2 peptide pool-682 
reactive CD4+ or CD8+ T cells were over 0.05% of CD4+ or CD8+ T cells, respectively. 683 
Cytokine responses were background subtracted individually prior to further analysis. Data 684 
shown are as median from 14 subjects with history of mild symptoms and 8 with severe 685 
symptoms. Mann-Whitney test was used for the analysis. Two-tailed p value was calculated. 686 
* P<0.05 687 
 688 
Fig. 5: Cytokine profile of SARS-Cov-2-specific T cells. Cytokine production of SARS-689 
Cov-2-specific T cells was assessed by intracellular cytokine staining after incubation with 690 
SARS-CoV-2 peptides. a) Pie charts represent the relative proportions of CD4+ or CD8+ T 691 
cells producing, and the relative proportion of T cells producing one, two and three cytokines 692 
IFN-γ, TNFα and IL-2. Different colored segments represented different pattern of cytokine 693 
production. b) Comparison of the frequency of multifunctional CD8+ T cells targeting Spike 694 
and M/NP.  The open circles and squares represent T cell responses in mild cases and 695 
severe cases, respectively. c) The relative frequencies of CD4+ and CD8+ T cells expressing 696 
CD107a after antigen-stimulation. Data shown are from 14 subjects with mild symptoms and 697 
8 with severe symptoms. Mann-Whitney test was used for the analysis. * P<0.05, **P<0.01 698 
 29
 699 
Fig. 6: Defined SARS-CoV-2-specific CD8 epitopes. a) List of identified optimal CD8 700 
epitopes; b) Examples of peptide-MHC Class I pentamers staining ex-vivo with PBMCs 701 
(HLA-B0702, B4001, A1101, A0101 and A0201) or with cultured cell lines (A0301).  702 
 703 
Fig. 7: Memory phenotype and differentiation status of SARS-CoV-2-specific CD8+ T 704 
cells. PBMC were isolated and stained with peptide-MHC class I Pentameric complexes and 705 
markers of T cell memory and differentiation. a) Representative FACS plots of gating for 706 
different cell subsets b) and c) Expression of memory markers (CCR7 and CD45RA) and 707 
differentiation markers (CD27 and CD28) on CD8+ Pentamer+ T cells, respectively (N= 7 708 
donors).  709 







